Nutritional Counseling for CSID Patients Taking Sucraid® (HCP)

IMPORTANT SAFETY INFORMATION:

Nutritional Support

Resources for Diet and Nutrition

Patients with Congenital Sucrase-Isomaltase Deficiency (CSID) who continue to experience any gastrointestinal (GI) symptoms while on Sucraid® therapy should be referred to a registered dietitian specializing in gastroenterology for diet assessment, education, and follow up. The dietitian can assist the patient with diet modifications and make sure they are still meeting their nutritional needs.

Diet modifications may be beneficial if a patient continues to have any GI symptoms after initiating Sucraid® therapy.

If a patient continues to experience gastrointestinal (GI) symptoms after one to two weeks on Sucraid® therapy, diet modification may be needed. A patient who is taking Sucraid® as prescribed should tolerate a normal amount of sucrose in the diet. Sucraid® does not replace the deficient isomaltase that aids in the digestion of maltose. Gradually reducing the amount of starch in the diet will decrease the amount of maltose, which may improve the patient’s lingering GI symptoms. A registered dietitian specializing in gastroenterology can work with the patient on dietary starch modification that may help alleviate any lingering GI symptoms.

Dietary Guides for Patients Treated with Sucraid®

Infant Dietary Guide

Infant Dietary Guide for Individuals Treated with Sucraid®

Child Dietary Guide

Child Dietary Guide for Individuals Treated with Sucraid®

Adult Dietary Guide

Adult Dietary Guide for Individuals Treated with Sucraid®

HOW TO READ A FOOD LABEL

How to Read a Food Label

For More Information and Resources

Call SucraidASSIST

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
  • Do not use Sucraid® (sacrosidase) Oral Solution with patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light.

Indication

Sucraid®(sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency (CSID).